BioHarvest Sciences (NASDAQ:BHST) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

BioHarvest Sciences (NASDAQ:BHST) posted its quarterly earnings data on Tuesday. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01, FiscalAI reports. The firm had revenue of $7.87 million for the quarter, compared to the consensus estimate of $9.31 million. BioHarvest Sciences had a negative net margin of 31.21% and a negative return on equity of 58.30%.

BioHarvest Sciences Price Performance

NASDAQ:BHST traded up $0.01 during trading hours on Thursday, reaching $1.75. 112,701 shares of the stock were exchanged, compared to its average volume of 35,362. BioHarvest Sciences has a twelve month low of $1.37 and a twelve month high of $8.30. The stock has a market cap of $34.43 million, a PE ratio of -3.37 and a beta of 0.93. The firm has a 50 day moving average of $1.65 and a 200 day moving average of $3.11.

Analyst Ratings Changes

BHST has been the subject of several recent research reports. Maxim Group lowered their target price on shares of BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Monday, September 14th. Finally, Roth Capital dropped their price target on shares of BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $6.50.

About BioHarvest Sciences

BioHarvest Sciences Inc. is a biotechnology company developing health and wellness products through its proprietary Botanical Synthesis technology. The platform is designed to produce plant-based compounds in controlled environments without relying on conventional agricultural cultivation of the whole plant, with the goal of preserving targeted botanical molecules and improving production consistency. The company’s primary commercial product is VINIA, a dietary supplement made from a proprietary red grape cell culture and marketed for its polyphenol content and potential cardiovascular and general wellness benefits.